SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs upcoming Phase 3 REGAL trial results for its GPS leukemia treatment dominate discussion, with topline data expected this month after the trial reached its final analysis milestone. Traders are split between optimism about a potential breakthrough and concern over the binary trial outcome, while sharp price swings have fueled debate about selling pressure and alleged short-term manipulation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is in focus ahead of the FDAs PDUFA decision on ivonescimab plus chemotherapy for EGFR-mutated lung cancer. Traders are split: bulls point to strong progression-free-survival results, improving survival trends and AstraZenecas backing, while bears emphasize that the trial missed statistical significance for overall survival and the FDA indicated that evidence was needed.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian shares are under pressure amid a broader pullback in EV and growth stocks, with traders also focused on the stocks persistent weakness and concerns about cash burn, profitability, and management. Some blame short sellers or trading dynamics, while bulls point to R2 progress and recent operating results as reasons for optimism; those explanations remain debated.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys strong Q3 resultsits first GAAP-profitable quarter, rapid growth in its Vector ad platform, and upbeat outlookhave fueled a sharp rebound and discussion of a possible turnaround. Reported takeover talks with Silver Lake and Saudi Arabias PIF add speculation, with traders debating whether the discussed valuation would undervalue the company or whether a deal will happen at all.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is selling off after lowering its revenue outlook amid delays activating third-party data-center capacity, prompting analyst concerns about execution and near-term growth; weakness across AI and neocloud stocks, alongside uncertainty around Nvidia, is adding pressure. Traders are split between viewing the delays and higher spending as serious risks and seeing them as temporary setbacks in a business with strong AI demand.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Buyout and partnership speculation, particularly involving Novo Nordisk, is fueling attention alongside unusually heavy trading; no deal is confirmed, and traders disagree over whether the move reflects real positioning or another rumor-driven swing. The discussion also centers on Vikings VK2735 obesity program and ObesityWeek presentations, while skeptics point to the longer wait for Phase 3 results.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure and the unresolved CEO succession are driving concern, with traders divided between those calling for his return and those worried about leadership continuity and scrutiny of Nvidias China-related chip sales. Upcoming earnings are another focus, but bullish bets on results and dip-buying compete with fears that uncertainty and further fallout could weigh on the stock.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos quarterly results beat expectations and its full-year outlook was raised, with strong demand for the Wegovy pill driving the improved outlook. Traders welcomed the evidence of a growth recovery but remain divided over whether oral Wegovy can offset diabetes weakness and competitive and pricing pressure from Lilly.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines is drawing attention over the squeeze from elevated jet-fuel costs, linked by traders to oil-market disruption and the Iran conflict, with recent earnings discussion highlighting that strong revenue has not translated into profits and the outlook has weakened. Bears worry about prolonged fuel pressure and AALs debt, while bulls see room for recovery if oil prices ease and travel demand remains firm.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUMs strong third-quarter results and rapid growth in its Quake AI GPU-cloud business are driving attention as the companys AI-infrastructure pivot gains traction. Bulls point to improving operations and the Anthropic-linked expansion, while skeptics focus on losses, cash needs and financing risks; short-squeeze claims remain speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?

Equity

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.


Direxion Shares ETF Trust - Direxion Daily Pharmaceutical & Medical Bull 3X ETF

Bullish Sentiment

<ul class="summary-bullets"><li>Eli Lilly announced it will pay $6.75 per share in cash, with additional milestone payments tied to the development of ATAI's two lead depression therapies.</li><li>The pharma giant said the acquisition strengthens its neuroscience pipeline with two late-stage programs targeting treatment-resistant depression.</li><li>Over the past year, Compass has significantly outperformed ATAI.</li></ul>Shares of AtaiBeckley Inc. (ATAI) and Compass Pathways (CMPS) surged in pre-market trade on Thursday, and both were among the top-trending tickers on Stockwits after Eli Lilly (LLY) confirmed it is acquiring AtaiBeckley.Lilly stated it will acquire all outstanding ATAI shares for $6.75 per share in cash at closing, plus up to $2.50 per share tied to future development and regulatory milestones for ATAI's two lead programs, bringing total potential value to as much as $9.25 per share.&nbsp;Based on ATAI's Wednesday close of around $5.36, the $6.75 per share cash offer represents a premium of approximately 25.9%. Taking total potential consideration of $9.25 into account, the premium to Wednesday's close would be approximately 72.6%.The deal is expected to close in the third quarter (Q3), pending shareholder and regulatory approval.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/ATAI_2026_07_16_06_37_17_png_4cad859a33.webp" alt="ATAI_2026-07-16_06-37-17.png" width="2643" height="1588"><figcaption>ATAI stock historical performance vs. pre-market on July 16. | Source: TradingView</figcaption></figure><a href="https://stocktwits.com/symbol/ATAI/">ATAI stock</a> jumped over 33% in pre-market trade, paring gains from a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-atai-stock-soaring-59-after-hours/cZZPl7dR7rk">jump of around 60%</a> earlier in the day. If pre-market grains hold, ATAI’s stock is on track to hit its highest levels since December 2021 and mark the biggest single-day jump in the company’s history.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260716_063534529_png_3a8bd239cd.webp" alt="koyfin_20260716_063534529.png" width="2400" height="1240"><figcaption>ATAI stock historical single-day stock price changes. | Source: Koyfin</figcaption></figure><a href="https://stocktwits.com/symbol/LLY">LLY's stock</a> was also among the top trending tickers on Stocktwits, edging higher by around 0.4% in pre-market trade.<h2 class="st-heading-2">What is Lilly Buying?</h2>ATAI's lead asset is BPL-003, an intranasal, synthetic form of 5-MeO-DMT for treatment-resistant depression that has already earned FDA Breakthrough Therapy Designation and entered Phase 3 activities, following a Phase 2b study showing rapid and durable symptom reduction after a roughly two-hour in-clinic session.&nbsp;Its second program, VLS-01, is a buccal film formulation of DMT currently in Phase 2b. "Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, Lilly Neuroscience's president.&nbsp;ATAI co-founder and CEO Srinivas Rao said the deal gives the company's pipeline "the resources and scale" to move faster than it could independently.<h2 class="st-heading-2">Why Is CMPS Stock Rallying Too?</h2><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> gained more than 7% in pre-market trade, and the move isn't purely coincidental. ATAI has historically been Compass's largest shareholder, though its stake has fallen from a peak of roughly 29% to 4.96% as of a February 2026 filing, dropping it below the 5% threshold requiring continued disclosure of its position.CMPS shares are also riding a separate, broader tailwind. Regulatory momentum for psychedelic therapies has been building steadily since President Donald Trump signed an executive order in April directing the Federal Drug Administration (FDA) to fast-track review of psychedelic drugs with Breakthrough Therapy designation.&nbsp;Earlier this week, the FDA announced a public hearing on psychedelic therapies and published final clinical guidance for developers on July 14. The Department of Health and Human Services (HHS) and the Department of Veterans Affairs also announced a new collaboration in anticipation of the first investigational drug approvals.&nbsp;<h2 class="st-heading-2">How Does Retail Feel About AtaiBeckley-Eli Lilly Deal?</h2>Retail sentiment around ATAI stock on Stocktwits rose to ‘extremely bullish’ from ‘bullish’ territory over the past day. Chatter stayed at ‘extremely high’ levels. Meanwhile, sentiment around CMPS stock fell to ‘neutral’ from ‘bullish’ territory, accompanied by chatter at ‘high’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_07_16_072103_png_95d0276b5f.webp" alt="Screenshot 2026-07-16 072103.png" width="1272" height="690"><figcaption>ATAI stock retail sentiment on July 16 as of 7:30 a.m. ET | Source: Stocktwits&nbsp;</figcaption></figure>Retail traders on the platform expressed excitement about what the takeover could mean for AtaiBeckley’s future growth.<stembedurl>https://www.stocktwits.com/LoadedUP1000/message/659184838</stembedurl><h2 class="st-heading-2">Comparing The Fundamentals</h2>The two companies sit at different stages of development. ATAI’s stock carries a ‘Strong Buy’ rating from two analysts, and a ‘Buy’ rating from 12 out of the 14 analysts covering the stock, according to Koyfin data. The average price target for the shares is around $14.17, and a trailing one-year return of about 102%.Wall Street was similarly bullish on Compass as well. CMPS Stock carries a ‘Strong Buy’ rating from three analysts and a ‘Buy’ rating from 12 out of the 15 analysts covering the stock. The average price target for the shares is around $24.47, implying a roughly 84% potential upside from Wednesday's close.Neither company currently generates meaningful revenue. Compass has posted essentially $0 in quarterly sales across every quarter tracked since early 2025, reflecting its status as a clinical-stage company with no approved products yet. Consensus estimates project continued losses, including a projected adjusted loss of $0.31 per share for the quarter ending June 30.&nbsp;ATAI shows a similar profile, with quarterly sales in the range of just $0 to $2 million and a projected adjusted loss of $0.11 per share for the same period.Over the past year, Compass has significantly outpaced ATAI since mid-April, gaining nearly 93% year-to-date versus ATAI's roughly 31%<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260716_061620094_png_c1a394bb97.webp" alt="koyfin_20260716_061620094.png" width="2400" height="1240"><figcaption>CMPS stock vs. ATAI stock performance year-to-date. | Source: Koyfin</figcaption></figure>Unlike ATAI, which will now become part of Eli Lilly, Compass remains an independent, publicly traded company focused on developing psychedelic therapies for treatment-resistant mental health conditions.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-says-53-b-offer-for-pay-pal-is-simply-too-low/cZZPR3LR7Ai">Michael Burry Says $53B Offer For PayPal Is 'Simply Too Low' – ‘The Big Short’ Investor Expects Higher Bid</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Eli Lilly logo on modern glass office building facade with partly cloudy sky, South San Francisco, California, October 16, 2025. (Photo by Smith Collection/Gado/Getty Images)

Shares of AtaiBeckley Inc. (ATAI) and Compass Pathways (CMPS) surged in pre-market trade on Thursday, and both were among the top-trending tickers on Stockwits after Eli Lilly (LLY) confirmed it is acquiring AtaiBeckley.

AtaiBeckley Inc.

COMPASS Pathways

Lilly(Eli) & Co

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

AdvisorShares Psychedelics ETF

SPDR Pharmaceuticals ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

PILL Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Fundamentals

Latest PILL News